Silo Pharma, Inc.: insider trades · United States · SEC (Form 4)

About Silo Pharma, Inc.

Silo Pharma, Inc. (Nasdaq: SILO) is a U.S.-listed developmental-stage biopharmaceutical company traded on the Nasdaq Stock Market in the United States. The company is best understood as an early-stage, non-diversified biotech platform focused on novel therapeutics and drug delivery systems for underserved conditions, particularly PTSD, stress-induced anxiety disorders, fibromyalgia, chronic pain, and central nervous system diseases. Its investment case is primarily scientific and pipeline-driven rather than commercial, with value creation tied to licensing, preclinical progress, clinical de-risking, and intellectual-property execution. ([silopharma.com](https://silopharma.com/about/?utm_source=openai)) The company’s roots go back to 2010, when it was originally incorporated, and it has since evolved through several corporate restructurings. Silo’s more recent corporate footprint is centered in Sarasota, Florida, where its principal executive offices are located. Public-company filings also indicate that the business has undergone changes in state of incorporation over time, reflecting the kind of corporate evolution often seen in micro-cap biotech names seeking a more efficient structure for growth and capital markets access. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/ea0282804-10k_silo.htm?utm_source=openai)) Silo’s pipeline is relatively compact but conceptually broad. Its lead program, SPC-15, is an intranasal candidate aimed at PTSD and stress-related anxiety disorders. SP-26 is a time-release ketamine-based implant being developed for fibromyalgia and chronic pain. The preclinical portfolio also includes SPC-14, an intranasal asset for Alzheimer’s disease, and SPU-16, a CNS-homing peptide with an initial research focus in multiple sclerosis. That mix gives Silo exposure to both conventional therapeutics and psychedelic-inspired or neurology-adjacent development themes. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1514183/000121390026035576/ea0282804-10k_silo.htm?utm_source=openai)) From a competitive standpoint, Silo Pharma occupies a speculative corner of the healthcare sector. It is competing in areas where data packages are still early, development timelines are long, and execution risk is high. Its collaboration-oriented model, including university and laboratory partnerships, may help reduce discovery costs and potentially support a 505(b)(2)-style regulatory pathway for certain assets. At the same time, the company remains highly dependent on external funding and on the ability to advance assets far enough to justify materially higher valuations. ([silopharma.com](https://silopharma.com/about/?utm_source=openai)) Recent corporate developments have been active. In 2025, Silo announced a registered direct offering and also disclosed a potential 50:50 joint venture with Hoth Therapeutics to develop an obesity and metabolic disease program. In 2026, the company announced a provisional patent filing for ibogaine-based therapeutics targeting traumatic brain injury and associated neuropsychiatric conditions, and it highlighted strategic relevance for its PTSD pipeline amid renewed policy attention on psychedelic-based treatments. For investors, the stock remains a highly event-driven Nasdaq micro-cap where news flow, financing, and pipeline milestones are likely to dominate the equity story. ([nasdaq.com](https://www.nasdaq.com/press-release/silo-pharma-announces-25-million-registered-direct-offering-priced-market-under?utm_source=openai))